{
    "name": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate",
    "comment": "Rx",
    "other_names": [
        "Balcoltra"
    ],
    "classes": [
        "Contraceptives",
        "Oral"
    ],
    "source": "https://reference.medscape.com/drug/balcoltra-levonorgestrel-oral-ethinylestradiol-ferrous-bisglycinate-1000222",
    "pregnancy": {
        "common": [
            "Contraindicated in pregnancy because there is no reason to use combined hormonal contraceptives (CHCs) in pregnancy (see Contraindications)",
            "Epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to CHCs before conception or during early pregnancy"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Combined hormonal contraceptives (CHCs) and/or metabolites are present in human milk and in breastfed infants",
            "CHCs, including levonorgestrel oral/ethinylestradiol/ferrous bisglycinate, can reduce milk production in breastfeeding females; reduction can occur at any time but is less likely to occur once breastfeeding",
            "Advise nursing female to use other methods of contraception until she discontinues breastfeeding"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Cigarette smoking & risk of cardiovascular disease",
                    "description": [
                        "Cigarette smoking increases risk of serious cardiovascular adverse effects from combination hormonal contraceptive use",
                        "This risk increases with age (>35 years) and with heavy smoking (15 or more cigarettes/day)",
                        "For this reason, combined hormonal contraceptives (CHCs) are contraindicated in women aged >35 years who smoke"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Liver tumors, benign or malignant, or liver disease (acute viral hepatitis or severe, decompensated, cirrhosis of the liver)",
                "Undiagnosed abnormal uterine bleeding",
                "Pregnancy (no reason to use CHCs during pregnancy)",
                "History or current breast cancer or other estrogen- or progestin-sensitive cancer",
                "Hypersensitivity",
                "Coadministration with ombitasvir/paritaprevir/ritonavir, with or without dasabuvir"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Risk of postpartum VTE decreases after third postpartum week, whereas risk of ovulation increases after third postpartum week; start contraceptive therapy no earlier than 4 weeks after delivery, in women who are not breastfeeding",
                "Acute or chronic disturbances of liver function may necessitate the discontinuation of CHCs use until liver function resolves to normal and CHC causation has been excluded",
                "Hepatic adenomas are associated with CHCs use; studies have shown an increased risk of developing hepatocellular carcinoma in long-term (>8 years) combined oral contraceptive (COC) users (see Contraindications)",
                "Studies suggest a small increased relative risk of developing gallbladder disease among CHC users; use of CHCs may worsen existing gallbladder disease; past history of CHC-related cholestasis predicts an increased risk with subsequent CHC use; women with a history of pregnancy-related cholestasis may be at an increased risk for CHC-related cholestasis",
                "CHCs may decrease glucose tolerance; carefully monitor in prediabetes and diabetes",
                "Consider alternative contraception for women with uncontrolled dyslipidemia",
                "Small proportion of women will have adverse lipid changes while on CHCs; women with hypertriglyceridemia, or a family history thereof, may be at an increased risk of pancreatitis when using CHCs",
                "If new headaches that are recurrent, persistent, or severe develop in women taking the drug, evaluate the cause and discontinue therapy if indicated (see Contraindications)",
                "This product contains FD&C yellow no. 5 (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons",
                "Carefully observe women with a history of depression, and discontinue therapy if depression recurs to a serious degree",
                "In women with hereditary angioedema, exogenous estrogens may induce or exacerbate symptoms of angioedema",
                "Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum; women with a tendency to chloasma should avoid exposure to the sun or ultraviolet light"
            ],
            "specific": [
                {
                    "type": "Bleeding irregularities and amenorrhea",
                    "description": [
                        "Unscheduled (breakthrough or intracyclic) bleeding and spotting may occur, especially during the first 3 months of use; if bleeding persists or occurs after previously regular cycles, check for causes such as pregnancy or malignancy; if pathology and pregnancy are excluded, bleeding irregularities may resolve over time or with a change to a different contraceptive product",
                        "If scheduled (withdrawal) bleeding does not occur, consider possibility of pregnancy; if patient has not adhered to prescribed dosing schedule (missed one or more active tablets or started taking them on a day later than she should have), consider possibility of pregnancy at time of first missed period and take appropriate diagnostic measures; if patient has adhered to prescribed regimen and misses two consecutive periods, rule out pregnancy",
                        "In clinical trial, 2.6% of the evaluable cycles were amenorrheic; women may experience amenorrhea or oligomenorrhea after discontinuation of CHCs, especially when such a condition was preexistent"
                    ]
                },
                {
                    "type": "Thrombotic disorders and other vascular problems",
                    "description": [
                        "Use of CHCs also increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events",
                        "CHCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes)",
                        "If feasible, discontinue CHC at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of VTE, as well as during the following prolonged immobilization",
                        "An increase in blood pressure has been reported in women taking CHCs, and this increase is more likely in older women with extended duration of use (see Contraindications); incidence of hypertension increases with increasing concentrations of progestin; monitor blood pressure periodically; stop therapy in women with well-controlled hypertension if blood pressure rises significantly"
                    ]
                },
                {
                    "type": "Drug interactions overview",
                    "description": [
                        "During clinical trials with the hepatitis C combination drug regimen containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, incidences of elevated ALT >5x ULN, including some cases >20x ULN, were significantly more frequent in women using ethinyl estradiol (EE)-containing medications, such as CHCs (see Contraindications)",
                        "Drugs or herbal products that induce certain enzymes, including CYP3A4, may decrease plasma concentrations of CHCs and potentially diminish the effectiveness of CHCs or increase breakthrough bleeding",
                        "Coadministration of atorvastatin or rosuvastatin and certain CHCs containing EE increase AUC values for EE by approximately 20-25%",
                        "Ascorbic acid and acetaminophen may increase plasma EE concentrations, possibly by inhibition of conjugation  CYP3A4 inhibitors (eg, itraconazole, voriconazole, fluconazole, grapefruit juice, ketoconazole) may increase plasma hormone concentrations",
                        "Significant changes (increase or decrease) in the plasma concentrations of estrogen and/or progestin have been noted in some cases of coadministration with HIV/HCV protease inhibitors and nonnucleoside reverse-transcriptase inhibitors  CHCs containing EE may inhibit the metabolism of other compounds (eg, cyclosporine, prednisolone, theophylline, tizanidine, voriconazole) and increase their plasma concentrations",
                        "CHCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, temazepam, and lamotrigine; significant decrease in plasma concentration of lamotrigine has been shown, likely due to induction of lamotrigine glucuronidation",
                        "Estrogen component of CHCs may raise the serum concentrations of thyroxine-binding globulin, sex hormone-binding globulin, and cortisol-binding globulin; dose of replacement thyroid hormone or cortisol therapy may need to be increased"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC)",
            "description": {
                "common": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate, ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC). unknown mechanism. Contraindicated. ALT elevations >5x ULN (including some >20x ULN) observed in clinical trials when ethinyl estradiol was coadministered with ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. Discontinue ethinyl estradiol-containing medications before initiating ombitasvir/paritaprevir/ritonavir, and/or dasabuvir. Restart ethinyl estradiol containing medication ~2 weeks after hepatitis C combination drug regimen completed."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "abametapir",
            "description": {
                "common": "abametapir will increase the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. If not feasible, avoid use of abametapir."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atazanavir",
            "description": {
                "common": "atazanavir, levonorgestrel oral/ethinylestradiol/ferrous bisglycinate. Other (see comment). Avoid or Use Alternate Drug. \nComment: Significant changes (increase or decrease) can occur in estrogen plasma levels. Efficacy of hormonal contraceptives may be reduced. Use of a nonhormonal contraceptive is recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "belzutifan",
            "description": {
                "common": "belzutifan will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of belzutifan with hormonal contraceptives may lead to contraceptive failure or increased breakthrough bleeding. Advise females of reproductive potential to use effective nonhormonal contraception. Based on animal studies, belzutifan can cause fetal harm."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "calaspargase pegol",
            "description": {
                "common": "calaspargase pegol, levonorgestrel oral/ethinylestradiol/ferrous bisglycinate. unknown mechanism. Avoid or Use Alternate Drug. Due to the potential for an indirect interaction between calaspargase pegol and oral contraceptives, concomitant use of these drugs is not recommended. Use another non-oral contraceptive method for females of childbearing potential."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "darunavir",
            "description": {
                "common": "darunavir, levonorgestrel oral/ethinylestradiol/ferrous bisglycinate. Other (see comment). Avoid or Use Alternate Drug. \nComment: Significant changes (increase or decrease) can occur in estrogen plasma levels. Efficacy of hormonal contraceptives may be reduced. Use of a nonhormonal contraceptive is recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "elagolix",
            "description": {
                "common": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate decreases effects of elagolix by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Based on the mechanism of action of elagolix, estrogen-containing contraceptives are expected to reduce elagolix efficacy. Effects of progestin-only contraceptives on the efficacy of elagolix is unknown. Advise women to use nonhormonal contraceptives during treatment with elagolix and for 1 week after discontinuing elagolix."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "encorafenib",
            "description": {
                "common": "encorafenib will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of encorafenib with hormonal contraceptives (CYP3A4 substrates) can result in decreased concentrations and loss of hormonal contraceptive efficacy. Encorafenib can cause fetal harm. Advise women of childbearing potential to use a highly effective nonhormonal contraceptive during treatment and for 2 weeks after final encorafenib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "indinavir",
            "description": {
                "common": "indinavir, levonorgestrel oral/ethinylestradiol/ferrous bisglycinate. Other (see comment). Avoid or Use Alternate Drug. \nComment: Significant changes (increase or decrease) can occur in estrogen plasma levels. Efficacy of hormonal contraceptives may be reduced. Use of a nonhormonal contraceptive is recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "isavuconazonium sulfate will increase the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lopinavir",
            "description": {
                "common": "lopinavir, levonorgestrel oral/ethinylestradiol/ferrous bisglycinate. Other (see comment). Avoid or Use Alternate Drug. \nComment: Significant changes (increase or decrease) can occur in estrogen plasma levels. Efficacy of hormonal contraceptives may be reduced. Use of a nonhormonal contraceptive is recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mavacamten",
            "description": {
                "common": "mavacamten will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Progestin and ethinyl estradiol are CYP3A4 substrates. Mavacamten may decrease systemic exposures of ethinyl estradiol and progestin, which may lead to contraceptive failure or an increase in breakthrough bleeding. Advise patients to use a contraceptive method that is not affected by CYP450 enzyme induction (eg, intrauterine system) or add nonhormonal contraception (eg, condoms) during coadministration and for 4 months after last mavacamten dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mobocertinib",
            "description": {
                "common": "mobocertinib will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of mobocertinib with hormonal contraceptives may lead to contraceptive failure or increased breakthrough bleeding. Advise females of reproductive potential to use effective non-hormonal contraception."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "nelfinavir, levonorgestrel oral/ethinylestradiol/ferrous bisglycinate. Other (see comment). Avoid or Use Alternate Drug. \nComment: Significant changes (increase or decrease) can occur in estrogen plasma levels. Efficacy of hormonal contraceptives may be reduced. Use of a nonhormonal contraceptive is recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nevirapine",
            "description": {
                "common": "nevirapine will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "omaveloxolone",
            "description": {
                "common": "omaveloxolone will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Omaveloxolone may reduce efficacy of hormonal contraceptives (eg, pill, patch, ring), implants, and progestin-only pills owing to weak CYP3A4 induction."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pexidartinib",
            "description": {
                "common": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate and pexidartinib both increase  Other (see comment). Avoid or Use Alternate Drug. Pexidartinib can cause hepatotoxicity. Avoid coadministration of pexidartinib with other products know to cause hepatoxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pretomanid",
            "description": {
                "common": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate, pretomanid.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Pretomanid regimen associated with hepatotoxicity. Avoid alcohol and hepatotoxic agents, including herbal supplements and drugs other than bedaquiline and linezolid."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir, levonorgestrel oral/ethinylestradiol/ferrous bisglycinate. Other (see comment). Avoid or Use Alternate Drug. \nComment: Significant changes (increase or decrease) can occur in estrogen plasma levels. Efficacy of hormonal contraceptives may be reduced. Use of a nonhormonal contraceptive is recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir, levonorgestrel oral/ethinylestradiol/ferrous bisglycinate. Other (see comment). Avoid or Use Alternate Drug. \nComment: Significant changes (increase or decrease) can occur in estrogen plasma levels. Efficacy of hormonal contraceptives may be reduced. Use of a nonhormonal contraceptive is recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tipranavir",
            "description": {
                "common": "tipranavir, levonorgestrel oral/ethinylestradiol/ferrous bisglycinate. Other (see comment). Avoid or Use Alternate Drug. \nComment: Significant changes (increase or decrease) can occur in estrogen plasma levels. Efficacy of hormonal contraceptives may be reduced. Use of a nonhormonal contraceptive is recommended."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acetaminophen",
            "description": {
                "common": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate will decrease the level or effect of acetaminophen by  unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acetaminophen IV",
            "description": {
                "common": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate will decrease the level or effect of acetaminophen IV by  unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acetaminophen rectal",
            "description": {
                "common": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate will decrease the level or effect of acetaminophen rectal by  unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alprazolam",
            "description": {
                "common": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate will increase the level or effect of alprazolam by  decreasing metabolism. Use Caution/Monitor. Ethinyl estradiol may inhibit the clearance of benzodiazepines that undergo oxidation, thereby increasing serum concentrations of concomitantly administered benzodiazepines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amobarbital",
            "description": {
                "common": "amobarbital will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amoxicillin",
            "description": {
                "common": "amoxicillin will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ampicillin",
            "description": {
                "common": "ampicillin will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aprepitant",
            "description": {
                "common": "aprepitant will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ascorbic acid",
            "description": {
                "common": "ascorbic acid increases levels of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by decreasing hepatic clearance. Use Caution/Monitor. Coadministration of ascorbic acid and certain combined hormonal contraceptives (CHCs) containing EE may increase plasma EE concentrations, possibly by inhibition of conjugation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atorvastatin",
            "description": {
                "common": "atorvastatin increases levels of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Coadministration of atorvastatin and certain combined hormonal contraceptives (CHCs) containing EE increase AUC values for EE by approximately 20-25%."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bosentan",
            "description": {
                "common": "bosentan will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brigatinib",
            "description": {
                "common": "brigatinib will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Brigatinib induces CYP3A4 in vitro. Coadministration of hormonal contraceptives with brigatinib can result in decreased concentrations and loss of efficacy. Brigatinib can cause fetal harm. Women should use an effective nonhormonal method of contraception during treatment and for at least 4 months after the last brigatinib dose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butabarbital",
            "description": {
                "common": "butabarbital will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butalbital",
            "description": {
                "common": "butalbital will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cefaclor",
            "description": {
                "common": "cefaclor will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cefadroxil",
            "description": {
                "common": "cefadroxil will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cefazolin",
            "description": {
                "common": "cefazolin will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cefdinir",
            "description": {
                "common": "cefdinir will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cefepime",
            "description": {
                "common": "cefepime will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cefixime",
            "description": {
                "common": "cefixime will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cefotaxime",
            "description": {
                "common": "cefotaxime will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cefprozil",
            "description": {
                "common": "cefprozil will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ceftazidime",
            "description": {
                "common": "ceftazidime will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ceftibuten",
            "description": {
                "common": "ceftibuten will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cefuroxime",
            "description": {
                "common": "cefuroxime will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cenobamate",
            "description": {
                "common": "cenobamate will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  unspecified interaction mechanism. Modify Therapy/Monitor Closely. Advise women to use additional or alternative non-hormonal birth control when concomitantly using cenobamate with oral contraceptives."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cephalexin",
            "description": {
                "common": "cephalexin will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chloramphenicol",
            "description": {
                "common": "chloramphenicol will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ciprofloxacin",
            "description": {
                "common": "ciprofloxacin will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "clarithromycin will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clindamycin",
            "description": {
                "common": "clindamycin will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clonazepam",
            "description": {
                "common": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate will increase the level or effect of clonazepam by  decreasing metabolism. Use Caution/Monitor. Ethinyl estradiol may inhibit the clearance of benzodiazepines that undergo oxidation, thereby increasing serum concentrations of concomitantly administered benzodiazepines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cobicistat",
            "description": {
                "common": "cobicistat will increase the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration with CYP3A4 inhibitors may increase the plasma hormone concentrations. Use of a nonhormonal contraceptive is recommended."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "colesevelam",
            "description": {
                "common": "colesevelam decreases levels of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Colesevelam, a bile acid sequestrant, given together with a combined hormonal contraceptives (CHCs), has been shown to significantly decrease the AUC of ethinyl estradiol (EE). Oral contraceptives containing ethinyl estradiol should be administered at least 4 hours before the colesevelam dose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "conivaptan",
            "description": {
                "common": "conivaptan will increase the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration with CYP3A4 inhibitors may increase the plasma hormone concentrations. Use of a nonhormonal contraceptive is recommended."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate, cyclosporine.\nEither increases levels of the other by decreasing metabolism. Use Caution/Monitor. Combined oral contraceptives containing EE may inhibit the metabolism and increase plasma concentrations of cyclosporine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dabrafenib",
            "description": {
                "common": "dabrafenib will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "demeclocycline",
            "description": {
                "common": "demeclocycline will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "dexamethasone will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazepam",
            "description": {
                "common": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate will increase the level or effect of diazepam by  decreasing metabolism. Use Caution/Monitor. Ethinyl estradiol may inhibit the clearance of benzodiazepines that undergo oxidation, thereby increasing serum concentrations of concomitantly administered benzodiazepines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dicloxacillin",
            "description": {
                "common": "dicloxacillin will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxycycline",
            "description": {
                "common": "doxycycline will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enzalutamide",
            "description": {
                "common": "enzalutamide will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin base",
            "description": {
                "common": "erythromycin base will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin ethylsuccinate",
            "description": {
                "common": "erythromycin ethylsuccinate will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin lactobionate",
            "description": {
                "common": "erythromycin lactobionate will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin stearate",
            "description": {
                "common": "erythromycin stearate will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eslicarbazepine acetate",
            "description": {
                "common": "eslicarbazepine acetate will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etravirine",
            "description": {
                "common": "etravirine will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosamprenavir",
            "description": {
                "common": "fosamprenavir will increase the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration with CYP3A4 inhibitors may increase the plasma hormone concentrations. Use of a nonhormonal contraceptive is recommended."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosaprepitant",
            "description": {
                "common": "fosaprepitant will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gemifloxacin",
            "description": {
                "common": "gemifloxacin will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "grapefruit",
            "description": {
                "common": "grapefruit will increase the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration with CYP3A4 inhibitors may increase the plasma hormone concentrations. Use of a nonhormonal contraceptive is recommended."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "griseofulvin",
            "description": {
                "common": "griseofulvin will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "idelalisib",
            "description": {
                "common": "idelalisib will increase the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration with CYP3A4 inhibitors may increase the plasma hormone concentrations. Use of a nonhormonal contraceptive is recommended."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imatinib",
            "description": {
                "common": "imatinib will increase the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration with CYP3A4 inhibitors may increase the plasma hormone concentrations. Use of a nonhormonal contraceptive is recommended."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isoniazid",
            "description": {
                "common": "isoniazid will increase the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration with CYP3A4 inhibitors may increase the plasma hormone concentrations. Use of a nonhormonal contraceptive is recommended."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "itraconazole",
            "description": {
                "common": "itraconazole will increase the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration with CYP3A4 inhibitors may increase the plasma hormone concentrations. Use of a nonhormonal contraceptive is recommended."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ivosidenib",
            "description": {
                "common": "ivosidenib will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  unspecified interaction mechanism. Modify Therapy/Monitor Closely. Coadministration of ivosidenib may decrease the concentrations of hormonal contraceptives, consider alternative methods of contraception in patients receiving ivosidenib. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketoconazole",
            "description": {
                "common": "ketoconazole will increase the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration with CYP3A4 inhibitors may increase the plasma hormone concentrations. Use of a nonhormonal contraceptive is recommended."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lamotrigine",
            "description": {
                "common": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate decreases levels of lamotrigine by unspecified interaction mechanism. Use Caution/Monitor. Significant decrease in plasma concentration of lamotrigine when concomitantly used with combined hormonal contraceptives (CHCs) containing EE, likely due to induction of lamotrigine glucuronidation. This may reduce seizure control; therefore, dosage adjustments of lamotrigine may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lesinurad",
            "description": {
                "common": "lesinurad will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levofloxacin",
            "description": {
                "common": "levofloxacin will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levoketoconazole",
            "description": {
                "common": "levoketoconazole will increase the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration with CYP3A4 inhibitors may increase the plasma hormone concentrations. Use of a nonhormonal contraceptive is recommended."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levothyroxine",
            "description": {
                "common": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate will decrease the level or effect of levothyroxine by  unknown mechanism. Modify Therapy/Monitor Closely. The estrogen component of combined hormonal contraceptives (CHCs) may raise the serum concentrations of thyroxine-binding globulin. Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone with use of CHCs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "liothyronine",
            "description": {
                "common": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate will decrease the level or effect of liothyronine by  unknown mechanism. Modify Therapy/Monitor Closely. The estrogen component of combined hormonal contraceptives (CHCs) may raise the serum concentrations of thyroxine-binding globulin. Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone with use of CHCs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "liotrix",
            "description": {
                "common": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate will decrease the level or effect of liotrix by  unknown mechanism. Modify Therapy/Monitor Closely. The estrogen component of combined hormonal contraceptives (CHCs) may raise the serum concentrations of thyroxine-binding globulin. Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone with use of CHCs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lixisenatide (DSC)",
            "description": {
                "common": "lixisenatide (DSC) will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. GLP1 agonists delay gastric emptying, which may affect absorption of concomitantly administered oral medications. Oral contraceptives should be taken at least 1 hr before lixisenatide administration or 11 hr after lixisenatide."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lumacaftor/ivacaftor",
            "description": {
                "common": "lumacaftor/ivacaftor will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metronidazole",
            "description": {
                "common": "metronidazole will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midazolam",
            "description": {
                "common": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate will increase the level or effect of midazolam by  decreasing metabolism. Use Caution/Monitor. Ethinyl estradiol may inhibit the clearance of benzodiazepines that undergo oxidation, thereby increasing serum concentrations of concomitantly administered benzodiazepines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mineral oil",
            "description": {
                "common": "mineral oil decreases levels of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "minocycline",
            "description": {
                "common": "minocycline will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mitotane",
            "description": {
                "common": "mitotane will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "morphine",
            "description": {
                "common": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate will decrease the level or effect of morphine by  unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "moxifloxacin",
            "description": {
                "common": "moxifloxacin will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nafcillin",
            "description": {
                "common": "nafcillin will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nefazodone",
            "description": {
                "common": "nefazodone will increase the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration with CYP3A4 inhibitors may increase the plasma hormone concentrations. Use of a nonhormonal contraceptive is recommended."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "neomycin PO",
            "description": {
                "common": "neomycin PO will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nicardipine",
            "description": {
                "common": "nicardipine will increase the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration with CYP3A4 inhibitors may increase the plasma hormone concentrations. Use of a nonhormonal contraceptive is recommended."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nitrofurantoin",
            "description": {
                "common": "nitrofurantoin will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ofloxacin",
            "description": {
                "common": "ofloxacin will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxcarbazepine",
            "description": {
                "common": "oxcarbazepine will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paromomycin",
            "description": {
                "common": "paromomycin will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "penicillin VK",
            "description": {
                "common": "penicillin VK will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "pentobarbital will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pitolisant",
            "description": {
                "common": "pitolisant will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Pitolisant is a borderline/weak inducer of CYP3A4. Monitor sensitive CYP3A4 substrates for reduced effectiveness if coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "posaconazole",
            "description": {
                "common": "posaconazole will increase the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration with CYP3A4 inhibitors may increase the plasma hormone concentrations. Use of a nonhormonal contraceptive is recommended."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prednisolone",
            "description": {
                "common": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate will increase the level or effect of prednisolone by  decreasing metabolism. Use Caution/Monitor. Combined oral contraceptives containing EE may inhibit the metabolism and increase plasma concentrations of cyclosporine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifabutin",
            "description": {
                "common": "rifabutin will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifapentine",
            "description": {
                "common": "rifapentine will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rosuvastatin",
            "description": {
                "common": "rosuvastatin increases levels of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Coadministration of rosuvastatin and certain combined hormonal contraceptives (CHCs) containing EE increase AUC values for EE by approximately 20-25%."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rufinamide",
            "description": {
                "common": "rufinamide will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salicylic acid acne",
            "description": {
                "common": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate will decrease the level or effect of salicylic acid acne by  unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "secobarbital",
            "description": {
                "common": "secobarbital will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "St John's Wort",
            "description": {
                "common": "St John's Wort will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfadiazine",
            "description": {
                "common": "sulfadiazine will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfamethoxazole",
            "description": {
                "common": "sulfamethoxazole will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfisoxazole",
            "description": {
                "common": "sulfisoxazole will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "temazepam",
            "description": {
                "common": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate will decrease the level or effect of temazepam by  unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tetracycline",
            "description": {
                "common": "tetracycline will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "theophylline",
            "description": {
                "common": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate will increase the level or effect of theophylline by  decreasing metabolism. Use Caution/Monitor. Combined oral contraceptives containing EE may inhibit the metabolism and increase plasma concentrations of cyclosporine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thyroid desiccated",
            "description": {
                "common": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate will decrease the level or effect of thyroid desiccated by  unknown mechanism. Modify Therapy/Monitor Closely. The estrogen component of combined hormonal contraceptives (CHCs) may raise the serum concentrations of thyroxine-binding globulin. Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone with use of CHCs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ticarcillin",
            "description": {
                "common": "ticarcillin will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tigecycline",
            "description": {
                "common": "tigecycline will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tizanidine",
            "description": {
                "common": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate will increase the level or effect of tizanidine by  decreasing metabolism. Use Caution/Monitor. Combined oral contraceptives containing EE may inhibit the metabolism and increase plasma concentrations of cyclosporine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "topiramate",
            "description": {
                "common": "topiramate will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The efficacy of hormonal contraceptives may be reduced. Use an alternative method of contraception or a backup method when enzyme inducers are used with combined hormonal contraceptives (CHCs), and continue backup contraception for 28 days after discontinuing enzyme inducer to ensure contraceptive reliability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triazolam",
            "description": {
                "common": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate will increase the level or effect of triazolam by  decreasing metabolism. Use Caution/Monitor. Ethinyl estradiol may inhibit the clearance of benzodiazepines that undergo oxidation, thereby increasing serum concentrations of concomitantly administered benzodiazepines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trimethoprim",
            "description": {
                "common": "trimethoprim will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by  altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voriconazole",
            "description": {
                "common": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate will increase the level or effect of voriconazole by  decreasing metabolism. Use Caution/Monitor. Combined oral contraceptives containing EE may inhibit the metabolism and increase plasma concentrations of cyclosporine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate increases effects of warfarin by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "enasidenib",
            "description": {
                "common": "enasidenib, levonorgestrel oral/ethinylestradiol/ferrous bisglycinate. unknown mechanism. Minor/Significance Unknown. Coadministration of enasidenib may increase or decrease the concentrations of combined hormonal contraceptives. Clinical significance of this interaction is unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": "14"
        },
        {
            "name": "Metrorrhagia",
            "percent": "8"
        },
        {
            "name": "Dysmenorrhea",
            "percent": "7"
        },
        {
            "name": "Nausea",
            "percent": "7"
        },
        {
            "name": "Abdominal pain",
            "percent": "4"
        },
        {
            "name": "Breast pain",
            "percent": "4"
        },
        {
            "name": "Emotional lability",
            "percent": "3"
        },
        {
            "name": "Acne",
            "percent": "3"
        },
        {
            "name": "Depression",
            "percent": "2"
        },
        {
            "name": "Amenorrhea",
            "percent": "2"
        },
        {
            "name": "Vaginal moniliasis",
            "percent": "2"
        },
        {
            "name": "Hypertension",
            "percent": null
        },
        {
            "name": "Hypercholesterolemia",
            "percent": null
        },
        {
            "name": "Weight gain",
            "percent": null
        },
        {
            "name": "Dysmenorrhea",
            "percent": null
        },
        {
            "name": "Flatulence",
            "percent": null
        },
        {
            "name": "Cardiac disorder",
            "percent": null
        },
        {
            "name": "Chest pain",
            "percent": null
        },
        {
            "name": "dyspnea",
            "percent": null
        },
        {
            "name": "palpitations",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "nausea",
            "percent": null
        },
        {
            "name": "vomiting",
            "percent": null
        },
        {
            "name": "diarrhea",
            "percent": null
        },
        {
            "name": "General disorders and administration site conditions",
            "percent": null
        },
        {
            "name": "Chest pain",
            "percent": null
        },
        {
            "name": "fatigue",
            "percent": null
        },
        {
            "name": "pain",
            "percent": null
        },
        {
            "name": "malaise",
            "percent": null
        },
        {
            "name": "injection site pain or erythema",
            "percent": null
        },
        {
            "name": "feeling abnormal",
            "percent": null
        },
        {
            "name": "pyrexia",
            "percent": null
        },
        {
            "name": "condition aggravated",
            "percent": null
        },
        {
            "name": "asthenia",
            "percent": null
        },
        {
            "name": "Immune system disorders",
            "percent": null
        },
        {
            "name": "Hypersensitivity reactions",
            "percent": null
        },
        {
            "name": "including pruritus",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        },
        {
            "name": "erythema",
            "percent": null
        },
        {
            "name": "Injury",
            "percent": null
        },
        {
            "name": "poisoning",
            "percent": null
        },
        {
            "name": "and procedural complications",
            "percent": null
        },
        {
            "name": "Injury",
            "percent": null
        },
        {
            "name": "Investigations",
            "percent": null
        },
        {
            "name": "Decreased weight",
            "percent": null
        },
        {
            "name": "Musculoskeletal and connective",
            "percent": null
        },
        {
            "name": "tissue disorders",
            "percent": null
        },
        {
            "name": "Pain in extremity",
            "percent": null
        },
        {
            "name": "arthralgia",
            "percent": null
        },
        {
            "name": "back pain",
            "percent": null
        },
        {
            "name": "muscle spasm",
            "percent": null
        },
        {
            "name": "Nervous system disorders",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "migraine",
            "percent": null
        },
        {
            "name": "dizziness",
            "percent": null
        },
        {
            "name": "hypoesthesia",
            "percent": null
        },
        {
            "name": "paresthesia",
            "percent": null
        },
        {
            "name": "Psychiatric disorders",
            "percent": null
        },
        {
            "name": "Depression",
            "percent": null
        },
        {
            "name": "insomnia",
            "percent": null
        },
        {
            "name": "anxiety",
            "percent": null
        },
        {
            "name": "Reproductive system and breast disorders",
            "percent": null
        },
        {
            "name": "Metrorrhagia",
            "percent": null
        },
        {
            "name": "menorrhagia",
            "percent": null
        },
        {
            "name": "hot flush",
            "percent": null
        },
        {
            "name": "vaginal hemorrhage",
            "percent": null
        },
        {
            "name": "Respiratory",
            "percent": null
        },
        {
            "name": "thoracic",
            "percent": null
        },
        {
            "name": "and mediastinal disorders",
            "percent": null
        },
        {
            "name": "Nasopharyngitis",
            "percent": null
        },
        {
            "name": "cough",
            "percent": null
        },
        {
            "name": "Sleep disorders and disturbances",
            "percent": null
        },
        {
            "name": "Somnolence",
            "percent": null
        },
        {
            "name": "Vascular disorders",
            "percent": null
        },
        {
            "name": "Deep vein thrombosis",
            "percent": null
        },
        {
            "name": "pulmonary embolism",
            "percent": null
        }
    ]
}